Description
Tarlatamab is indicated for the treatment of adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.
Tarlatamab was approved for medical use in the United States in May 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
IMDELLTRA (tarlatamab-dlle) for injection, for intravenous use Initial U.S. Approval: 2024
See full prescribing information: Click Here
Contact Sourcing Facilitation Team
Contact Name: Mr. Tarun Garg
Address: 60/4, Yusaf Sarai, Near Indian Oil Corp., New Delhi – 110 016 (India)
Mobile/WhatsApp. 9891296838.
Email: support@southdelhipharma.com, southdelhipharma@gmail.com
Get Access Imdelltra (tarlatamab-dlle) In India on request.
Imdelltra may be imported for personal treatment under the Named Patient Program (NPP) across India, including Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Aurangabad, Pune, Bengaluru, Hyderabad, Chennai, Visakhapatnam, Coimbatore, and other regions of India.
Note: South Delhi Pharma, act as a facilitation partner and do not manufacture, sell, or distribute pharmaceutical products. All facilitation activities are conducted in accordance with applicable Indian pharmaceutical and trade regulations.
